# Randomized, Double Blind Trial of the Quadrivalent HPV Vaccine to Improve Responses to LEEP Treatment of Cervical HSIL

> **NCT01928225** · PHASE2 · COMPLETED · sponsor: **University of Witwatersrand, South Africa** · enrollment: 180 (actual)

## Conditions studied

- Cervical High Grade Squamous Intraepithelial Lesion

## Interventions

- **BIOLOGICAL:** Human Papillomavirus vaccine

## Key facts

- **NCT ID:** NCT01928225
- **Lead sponsor:** University of Witwatersrand, South Africa
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09-02
- **Primary completion:** 2017-11-30
- **Final completion:** 2018-03-01
- **Target enrollment:** 180 (ACTUAL)
- **Last updated:** 2020-06-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01928225

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01928225, "Randomized, Double Blind Trial of the Quadrivalent HPV Vaccine to Improve Responses to LEEP Treatment of Cervical HSIL". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01928225. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*